Miravo Healthcare to present at the Q1 Virtual Investor Summit
March 11, 2021 07:35 ET
|
Nuvo Pharmaceuticals Inc.
MISSISSAUGA, Ontario, March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare™ today announced that Jesse Ledger, President...
Intrommune Therapeutics Publishes Peanut Allergy and Immunotherapy Report
February 23, 2021 12:00 ET
|
Intrommune Therapeutics
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly immunotherapy platform for the treatment of...
AAFA’s 2021 Allergy Capitals™ Report Ranks Top U.S. Cities for Seasonal Allergies
February 23, 2021 05:00 ET
|
Asthma and Allergy Foundation of America
Washington D.C., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Today, the Asthma and Allergy Foundation of America (AAFA) released its annual Allergy Capitals™ report for 2021. The report identifies the most...
Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301
February 04, 2021 09:13 ET
|
Intrommune Therapeutics
NEW YORK, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Intrommune to Participate in BIO @ JPM During “J.P. Morgan Week 2021”
January 07, 2021 17:35 ET
|
Intrommune Therapeutics
NEW YORK, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, will...
Global Cough, Cold & Allergy (CCA) Treatment Market Report 2020-2024: Market is Expected to Reach US$35.36 billion - Rising Sales of Over-the-Counter (OTC) Medicines
January 05, 2021 06:03 ET
|
Research and Markets
Dublin, Jan. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Cough, Cold & Allergy (CCA) Treatment Market (By Product Category, End-Users & Region): Insights & Forecast with Potential Impact of...
Intrommune Therapeutics Strikes Deal with Circuit Clinical®
October 20, 2020 10:00 ET
|
Intrommune Therapeutics
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics has announced an expanded partnership with Circuit Clinical, a leading Integrated Research Organization (IRO). Based on this deal,...
Recent Peer-Reviewed Publication Supports Immunotherapy for the Treatment of Food Allergies
October 08, 2020 09:50 ET
|
Intrommune Therapeutics
NEW YORK, Oct. 08, 2020 (GLOBE NEWSWIRE) -- A recent publication in the journal Immunotherapy reviews a variety of immunotherapy platforms for the treatment of food allergies. The article,...
Intrommune Therapeutics Featured at Upcoming Investor Conferences
October 05, 2020 14:55 ET
|
Intrommune Therapeutics
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Cross Keys Capital Advises Atlanta Allergy & Asthma Clinic on Partnership with Southern Ear, Nose, Throat & Allergy Partners
September 30, 2020 17:59 ET
|
Cross Keys Capital, LLC.
Fort Lauderdale, Florida, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Cross Keys Capital served as the exclusive M&A advisor to Atlanta Allergy & Asthma Clinic ("Atlanta Allergy") in its partnership...